<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Chemoradiotherapy has improved the outcome of patients with <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although a sufficiently long-time survival has resulted in the increase of several treatment-related late toxicities, little is still known about the incidence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In our hospital, 348 patients with <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> received chemotherapy consisting of <z:chebi fb="0" ids="31898">nedaplatin</z:chebi> and <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> and concurrent irradiation </plain></SENT>
<SENT sid="3" pm="."><plain>Median and average follow-up durations were 8 and 21 months (1-92), respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Four patients developed <z:hpo ids='HP_0001909'>leukemia</z:hpo> after 19-48 months of follow-up </plain></SENT>
<SENT sid="5" pm="."><plain>Two patients were diagnosed with overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> presenting a complex karyotype, including the deletion of chromosome 5 or 7 </plain></SENT>
<SENT sid="6" pm="."><plain>Notably, one patient showed an additional chromosomal abnormality with t(9;22)(q34;q11) </plain></SENT>
<SENT sid="7" pm="."><plain>Other patients developed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with t(9;22)(q34;q11) and Burkitt <z:hpo ids='HP_0001909'>leukemia</z:hpo> with t(8;14)(q24;q32) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients eventually succumbed to <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="240" ids="33364,33400">Platinum</z:chebi> and fluorouracil have shown relatively lower risks for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> in comparison with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> and <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Especially, <z:chebi fb="0" ids="31898">nedaplatin</z:chebi> has never been described to introduce secondary <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Our report supports the idea that the concurrent administration of radiotherapy with these agents affects the risk of <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Interestingly, rare balanced chromosomal abnormalities were observed in the present cases, thus providing new insights into the <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> of therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>